JRSIS HEALTH CARE Corp - FORM 10-Q

Attached files

file	filename
EX-32.2 - EXHIBIT 32.2 - JRSIS HEALTH CARE Corp	tv479164_ex32-2.htm
EX-32.1 - EXHIBIT 32.1 - JRSIS HEALTH CARE Corp	tv479164_ex32-1.htm
EX-31.2 - EXHIBIT 31.2 - JRSIS HEALTH CARE Corp	tv479164_ex31-2.htm
EX-31.1 - EXHIBIT 31.1 - JRSIS HEALTH CARE Corp	tv479164_ex31-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-36758

JRSIS HEALTH CARE CORPORATION.

(Exact name of Registrant as specified in its charter)

Florida	8099	46-4562047
(State or other jurisdiction of	(Primary Standard Industrial	(I.R.S. Employer
incorporation or organization)	Classification Code Number)	Identification Number)

1 ^st – 7 ^th Floor, Industrial and Commercial Bank Building,

Xingfu Street, Hulan Town, Hulan District, Harbin City,

Heilongjiang Province, China 150025

(Address, including zip code, and telephone number, including area code,

of Registrant’s principal executive offices)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 (Exchange Act) during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨
Non-accelerated filer o (Do not check if a smaller reporting company)	Smaller reporting company x
	Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

As of the date of filing of this report, there were outstanding 13,915,000 shares of the issuer’s common stock, par value $0.001 per share.

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION		3

Item 1	Consolidated Financial Statements	3

Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4

Item 3	Quantitative and Qualitative Disclosures About Market Risk	12

Item 4	Controls and Procedures	12

PART II – OTHER INFORMATION		13

Item 1	Legal Proceedings	13

Item 1A	Risk Factors	13

Item 2	Unregistered Sale of Equity Securities and Use of Proceeds	13

Item 3	Defaults Upon Senior Securities	13

Item 4	Mine Safety Disclosures	13

Item 5	Other Information	13

Item 6	Exhibits	13

	Signatures	14

PART I – FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Item Regulation S-X, Rule 10-01(c) Interim Financial Statements, and, therefore, do not include all information and footnotes necessary for a complete presentation of financial position, results of operations, cash flows, and stockholders' equity in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. Operating results for the three and nine months ended September 30, 2017 are not necessarily indicative of the results that can be expected for the year ended December 31, 2017.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	Page

JRSIS HEALTH CARE CORPORATION

Consolidated Balance Sheets— September 30, 2017 (Unaudited) and December 31, 2016	F-2

Consolidated Statements of Operations and Comprehensive Income for the Three and Nine Months Ended September 30, 2017 and 2016 (Unaudited)	F-3

Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2017 and 2016 (Unaudited)	F-4

Notes to Consolidated Financial Statements (Unaudited)	F5-18

F-1

JRSIS HEALTH CARE CORPORATION

CONSOLIDATED BALANCE SHEETS

(AMOUNTS IN USD, EXCEPT SHARES)

	September 30,			December 31,
	2017			2016
	(Unaudited)			(Audited)

Assets
Current Assets:
Cash and cash equivalents	$	999,648		$	890,662
Accounts receivable, net		4,011,489			3,335,500
Inventories		1,083,242			801,240
Other receivables		3,261			1,555
Prepayments		814,531			518,722
Amount due from related parties		3,641,787			1,804,987
Deferred expenses		67,797			64,967
Total current assets		10,621,755			7,417,633
Construction in progress		1,754,719			-
Property and equipment, net		24,508,268			23,274,180
Long term deferred expenses		121,001			164,676
Deposits for capital leases		819,543			846,101
Total assets	$	37,825,286		$	31,702,590

Liabilities and shareholders’ equity
Current Liabilities:
Accounts payable	$	1,505,516		$	743,660
Short-term bank loan		435,769			-
Deposits received		5,325			5,751
Amount due to related parties		155,699			25,329
Other payable		748,013			77,973
Payroll payable		56,938			52,072
Capital lease obligations - current portion		1,214,281			2,313,038
Total current liabilities		4,121,541			3,217,823

Capital lease obligations		16,446,949			16,222,992
Other capital lease payable		585,898			574,921
Total liabilities	$	21,154,388		$	20,015,736

Shareholders’ equity
Common stock; $0.001 par value, 100,000,000 shares authorized; 13,915,000 and 13,915,000 issued and outstanding at September 30, 2017 and December 31, 2016, respectively		13,915			13,915
Additional Paid-in capital		1,132,423			1,132,423
Retained earnings		9,354,792			6,274,052
Other comprehensive income		(392,935	)		(786,055	)
Total shareholders’ equity of the Company		10,108,195			6,634,335
Non-controlling interest		6,562,703			5,052,519
Total shareholders’ equity		16,670,898			11,686,854
Total liabilities and shareholders’ equity	$	37,825,286		$	31,702,590

See notes to consolidated financial statements

F-2

JRSIS HEALTH CARE CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(AMOUNTS IN USD, EXCEPT SHARES)(UNAUDITED)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016

Revenue:
Medicine	$	2,407,174		$	1,846,898		$	7,356,170		$	5,643,897
Patient services		3,315,923			2,410,346			9,236,136			7,314,215
Total revenue		5,723,097			4,257,244			16,592,306			12,958,112
Operating costs and expenses:
Cost of medicine sold		1,573,420			1,161,959			4,799,786			3,374,138
Medical consumables		648,258			382,891			1,755,032			1,200,169
Salaries and benefits		934,950			720,860			2,643,753			2,106,103
Office supplies		249,389			70,142			581,678			220,380
Vehicle expenses		22,842			17,374			65,667			38,770
Utilities expenses		74,222			76,027			293,706			308,358
Rentals and lease		5,877			-			5,877			-
Advertising and promotion expenses		22,869			15,868			59,064			92,975
Interest expense		351,137			339,737			980,451			1,030,949
Professional fee		15,869			19,351			54,182			126,272
Depreciation		322,476			282,302			936,827			779,321
Total operating costs and expenses		4,221,309			3,086,511			12,176,023			9,277,435
Earnings from operations before other income and income taxes		1,501,788			1,170,733			4,416,283			3,680,677
Other income (expenses)		7,108			(857	)		(13,155	)		3,900
Earnings from operations before income taxes		1,508,896			1,169,876			4,403,128			3,684,577
Income tax		437			866			2,072			3,172
Net income		1,508,459			1,169,010			4,401,056			3,681,405
Less: net income attributable to non-controlling interests		452,538			355,950			1,320,317			1,133,290
Net income attributable to the Company	$	1,055,921		$	813,060		$	3,080,739		$	2,548,115
Comprehensive income:
Foreign currency translation adjustment attributable to non-controlling interests		(86,880	)		11,530			(189,867	)		77,759
Foreign currency translation adjustment attributable to the Company		(203,045	)		27,126			(393,121	)		195,169
Comprehensive income	$	1,798,384		$	1,130,354		$	4,984,044		$	3,408,477
Less: Comprehensive income attributable to non-controlling interests		539,418			344,420			1,510,184			1,055,531
Comprehensive income attributable to the Company	$	1,258,966		$	785,934		$	3,473,860		$	2,352,946

Basic and diluted earnings per share	$	0.0759		$	0.0584		$	0.2214		$	0.1831
Weighted average number of shares outstanding		13,915,000			13,915,000			13,915,000			13,915,000

See notes to consolidated financial statements

F-3

JRSIS HEALTH CARE CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(AMOUNTS IN USD, EXCEPT SHARES) (UNAUDITED)

	Nine Months Ended September 30,
	2017			2016

Cash Flows from Operating Activities
Net income	$	4,401,056		$	3,681,405
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		936,827			779,321
Interest		980,451			1,030,949
Changes in operating assets and liabilities:
Accounts receivable, net		(518,881	)		(445,404	)
Inventories		(241,598	)		(333,473	)
Amount due from related parties		(1,721,979	)		(531,897	)
Prepayments and other current assets		(454,662	)		(446,649	)
Accounts payable		713,214			303,474
Amount due to related parties		161,232			(191,282	)
Deposits received		(661	)		(507	)
Accrued expenses and other current liabilities		(95,108	)		68,086
Net cash provided by operating activities		4,159,891			3,914,023

Cash Flows from Investing Activities
Purchases of fixed assets		(630,043	)		(3,346,535	)
Prepayment for fixed assets acquisition		(261,101	)		428,106
Payment of Construction in progress		(1,715,630	)		-
Net cash used in investing activities		(2,606,774	)		(2,918,429	)

Cash Flows from Financing Activities
Proceeds from shareholders		720,000			-
Payments on capital lease obligation		(2,565,420	)		(2,149,599	)
Proceeds from related parties		-			75,985
Proceeds from capital lease		-			904,854
Short-term bank loan		408,836			421,331
Net cash used in financing activities		(1,436,584	)		(747,429	)

Effect of exchange rate fluctuation on cash and cash equivalents		(7,547	)		(3,296	)
Net increase (decrease) in cash and cash equivalents		108,986			244,869

Cash and cash equivalents, beginning of period		890,662			352,153
Cash and cash equivalents, ending of period	$	999,648		$	597,022

Supplemental disclosure of cash flow information
Cash paid for income taxes		2,072			3,172
Cash paid for interest		980,451			1,030,949

See notes to consolidated financial statements

F-4

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 1. DESCRIPTION OF BUSINESS AND ORGANIZATION

JRSIS HEALTH CARE CORPORATION (the “Company” or “JHCC”) was incorporated on November 20, 2013 under the laws of the United States and the State of Florida. The general nature of the business shall be to engage in any and all lawful business permitted under the laws of the United States and the State of Florida.

JRSIS HEALTH CARE LIMITED (“JHCL”), formally named China Runteng Medical Group Co., Ltd, which is a privately held Limited Liability Company registered in British Virgin Island (“BVI”) on February 25, 2013. JHCL was authorized to issue 50,000 shares of a single class each with par value of $1.00 per share to its sole shareholder Ms. Yanhua Xing. On November 20, 2013, China Runteng Medical Group Co., Ltd has changed its name to JRSIS HEALTH CARE LIMITED.

Runteng Medical Group Co., Ltd (“Runteng”) is a privately held limited liability company registered in Hong Kong on September 17, 2012. Runteng was authorized to issue up to 10,000 shares with par value of HK$1 per share to its sole shareholder Ms. Yanhua Xing.

Harbin Jiarun Hospital Co., Ltd (“Jiarun”) was a privately held, for-profit hospital, incorporated in Harbin city of Heilongjiang, China in February 2006. Jiarun is a private hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents of Harbin. After a series of share exchanges mentioned here after in note 1, Jiarun became a 70% owned subsidiary of the Company.

JHCC, JHCL, Runteng and Jiarun are collectively referred as the “Group”.

Reorganization

On December 23, 2012, in accordance with the “Foreign Investment Enterprise Law” under the People’s Republic of China (“PRC”), Runteng and Jiarun entered into an agreement that Runteng and the original owner of Jiarun should invest a total of RMB50,000,000 ($7,936,508), in which Runteng and the original owner should contribute RMB35,000,000 ($5,555,556) or 70% and RMB15,000,000 ($2,380,952) or 30% of the total capital, respectively. According to the Article of Association (Joint venture investment agreement) and the amendment of Article of Association (Joint venture investment agreement), Runteng has the obligation to pay RMB35,000,000 ($5,555,556) within five years after the issuance of the joint venture business license. As of September 30, 2017, Jiarun has received $1,081,000 from Runteng.

On March 7, 2013, JHCL acquired all 100 issued and outstanding shares of through share exchanges to obtain 100% controlling interests of Runteng.

On June 1, 2013, Junsheng Zhang, the owner of Jiarun, entered into a supplemental agreement with Runteng for the attribution of accumulated retained earnings of Jiarun. In which, the historical accumulated profit of Jiarun up to June 30, 2013, should be 100% attributed to Junsheng Zhang; the profit generated from Jiarun after July 1, 2013, should be attributed to Runteng and Junsheng Zhang on the basis of 70% and 30%, respectively.

On July 29, 2013, the Joint Venture Investment Agreement between Runteng and Junsheng Zhang has been approved by the Development and Reform Commission of Hulan District, Harbin City and Harbin Investment Promotion Bureau. On the same date, Jiarun has obtained Certificate of Approval for Establishment of Enterprises with Investment of Taiwan, Hong Kong, Macao and Overseas Chinese in the People’s Republic of China; the Joint Venture Jiarun duration of operation is twenty years.

F-5

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 1. DESCRIPTION OF BUSINESS AND ORGANIZATION (CONTINUED)

On October 3, 2013, Ms. Yanhua Xing transferred 23,275 JHCL shares to Mr. Junsheng Zhang, 23,225 JHCL shares to Ms. Chunlan Tang, and 1,050 JHCL shares to Mr. Weiguang Song.

On November 8, 2013, Ms. Chunlan Tang transferred all 23,225 JHCL shares to Mr. Junsheng Zhang, subsequently making Mr. Junsheng Zhang holdings 46,500 JHCL shares.

On December 20, 2013, a share exchange agreement was entered by and among JHCC, JHCL and the shareholders of JHCL, Junsheng Zhang, Yanhua Xing and Weiguang Song. JHCC desires to issue a total of 12,000,000 shares of its Common Stock (the “JHCC Shares”) to the Shareholders of JHCC, pro rata, in exchange for 100% of the JHCL Shares owned by the Shareholders. At the Closing, the Shareholders shall allot and deliver to JHCC a total of 50,000 shares of the ordinary share of JHCL which represents 100% of the issued and outstanding shares of JHCL. JHCL shall become a wholly-owned subsidiary of JHCC, and JHCC will effectively acquire all business and an assets of JHCL as now or hereafter existing, including all business and assets of any and all subsidiaries of JHCL, including 70% ownership interest in Jiarun.

On July 8, 2014, Jiarun obtained joint venture business license. Runteng has already completed cooperation restructuring. Up to completion of the legal structures, Jiarun are compliance with the Company Law of People’s Republic of China and all other requirements imposed by PRC authorities.

Before and after the reorganization mentioned above, Junsheng Zhang continued to serve as chairman of Jiarun (the “Operating Subsidiary”), and together with the other management of the Company, continued to direct both day-to-day operation and management of the Operating Subsidiary, as well as its strategic direction. The reorganization effectively resulted in Junsheng Zhang continuing to bear the residual risks and rewards related to the Operating Subsidiary. Because of the reasons described above, the Company is substantively controlled by Junsheng Zhang, and the Company continued to consolidate the Operating subsidiary during the reorganization. And the reorganization transactions are considered as a series of transactions between the parties under common control and did not establish a new basis in the assets and liabilities of the Operating Subsidiary.

During the reorganization, JHCC, JHCL, Runteng and Jiarun were under common control of Junsheng Zhang. Therefore, the reorganization was effectively a legal recapitalization accounted for as transactions between entities under common control at the carry over basis, in a manner similar to pooling-of-interests accounting. The effect of the reorganization was applied retroactively to the prior years’ consolidated financial statements as if the current structure existed since inception.

30% of Jiarun hospital interest held by Junsheng Zhang is subjecting to non-controlling interest (“NCIs”), which was stated under ASC810-10-45, the ownership interest in the subsidiary that are held by owners other than the parent is a non-controlling interest. 70% held by Runteng is applying to its holding Runteng. According to the supplemental agreement signed between Junsheng Zhang and Runteng on June 1, 2013, the comprehensive income from Jiarun would be attributable to retained earnings and non-controlling interest for 70% and 30% respectively, from July 1, 2013.

NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The consolidated financial statements have been prepared in accordance with the United States generally accepted accounting principles (“U.S. GAAP”).

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. Non-controlling interests represent the equity interest in Jiarun that is not attributable to the Company. Non-controlling interest is reported in the consolidated financial position within equity, separately from the Company’s equity and that net income or loss and comprehensive income or loss are attributable to the Company’s and the non-controlling interest.

F-6

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Use of estimates

The preparation of unaudited consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however actual results could differ from those estimates. Significant items subject to such estimates and assumptions include valuation allowances for receivables and recoverability of carrying amount and the estimated useful lives of long-lived assets. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.

Functional currency and foreign currency translation

JHCC and JHCL’s functional currency is the United States dollar (“US$”). Runteng’s functional currency is the Hong Kong dollar (“HK$”). The functional currency of Jiarun is the Renminbi (“RMB”).

The Company’s reporting currency is US$. Assets and liabilities of Runteng and Jiarun are translated at the current exchange rate at the balance sheet dates, revenues and expenses are translated at the average exchange rates during the reporting periods, and equity accounts are translated at historical rates. Translation adjustments are reported in other comprehensive income.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk are cash, accounts receivable and other receivables arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions. The Company has a diversified customer base. The majority of sales are either cash receipt in advance or cash receipt upon delivery. For the three months ended September 30, 2017 and 2016, no customer accounted for more than 10% of net revenue. As of September 30, 2017 and December 31, 2016, 3 and 2 customers, respectively, accounted for more than 10% of net accounts receivable, respectively. For those credit sales, the Company routinely assesses the financial strength of its customers and, based upon factors surrounding the credit risk, establishes an allowance, if required, for uncollectible accounts and, as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is limited.

Cash and cash equivalents

Cash and cash equivalents include all cash, deposits in banks and other liquid investments with initial maturities of three months or less.

Accounts receivable

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

Inventories

Inventories, consisting principally of medicines, are stated at the lower of cost or market using the first-in, first-out method (“FIFO”). This policy requires the Company to make estimates regarding the market value of inventory, including an assessment of excess or obsolete inventory. The Company determines excess or obsolete inventory based on an estimate of the future demand and estimated selling prices for its products.

Construction in progress

Construction in progress represents the new hospital painting and decoration costs. And all direct costs relating to the polishing and decoration are capitalized as construction in progress. No depreciation is provided in respect of construction in progress.

F-7

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Property and equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.

Buildings and improvement	10-40 years
Medical equipment	5-15 years
Transportation instrument	5-10 years
Office equipment	5-10 years
Electronic equipment	5-10 years
Software	5-10 years

Leases

Operating lease

Leases where substantially all the rewards and risks of ownership of assets remain with the lessor are accounted for as operating leases. Minimum lease payments, including scheduled rent increases, made under operating leases are charged to the consolidated statements of operations and other comprehensive income (loss) on a straight-line basis over the lease term. Contingent rentals are excluded from minimum lease payments, and are recognized as expense when the achievement of the specified target is considered probable.

Capital lease

Leases which substantially transfer all of the benefits and risks inherent in ownership to the lessee are classified as capital leases. In a capital lease, assets and liabilities are recorded at the amount of the lesser of (a) the fair value of the leased asset at the inception of the lease or (b) the present value of the minimum lease payments (excluding executing costs) over the lease term. Recorded assets are depreciated over their estimated useful lives. During the lease term, each minimum lease payment is allocated between a reduction of the obligation and interest expense to produce a constant periodic rate of interest on the remaining balance of the obligation. Leasehold improvements are depreciated over the depreciable lives of the corresponding fixed asset or the related lease term, whichever is shorter.

Fair Value Measurement

The Company applies the provisions of ASC Subtopic 820-10, Fair Value Measurements, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

Fair value is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability.

ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs that may be used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs that is observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

There were no transfers between level 1, level 2 or level 3 measurements for the nine months ended September 30, 2017 and 2016.

Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are reflected in the accompanying consolidated financial statements at amounts that approximate fair value because of the short-term nature of these instruments. The fair value of the Company’s capital lease obligations also approximate carrying value as they bear interest at current market rates.

Segment and geographic information

The Company is operating in one segment in accordance with the accounting guidance FASB ASC topic 280, “Segment Reporting”. The Company’s revenues are from customers in People’s Republic of China (“PRC”). All assets of the Company are located in PRC.

F-8

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Revenue recognition

The Company recognizes revenue when the amount of revenue can be reliably measured, it is probable that economic benefits will flow to the entity and specific criteria have been met for each of the Company’s activities as described below.

Medicine sales

Revenue from the sale of medicine is recognized when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine.

Given the nature of this revenue source of the Company’s business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.

Patient Services

In accordance with the medical licenses of Jiarun, the approved medical patient service scope of the Company include medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.

Patient service revenue is recognized when it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.

The Company provides services to both patients covered by social insurance and patients who are not covered by social insurance. The Company charges the same rates for patient services regardless of the coverage by social insurance.

Patients who are not covered by social insurance are liable for the total cost of medical treatment.

•

For out-patient medical services, revenue is recognized when the Company provides medical service to the patient. The Company collects payment when the patient checks out from the hospital, which is the same day the services are provided.

•

For in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients’ symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received.

During the in-patient services period, the Company recognizes revenue when the patient service is provided and deducts the cost of service from the deposit received. The Company records these transactions based on daily reports generated by the respective medical department. When medical services exceed patient deposits received the Company records revenue and accounts receivable when the patient services are provided.

When patients check out from the hospital, the Company calculates and determines the remaining deposit, if any, and refunds the unused portion of the deposit to the patients. In the case where the patients have a balance in accounts receivable during the in-patient period, accounts receivable are required to be paid in full at checkout.

Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.

Settlement process

The Company is a registered medical service vendor under the state social insurance system for various social insurance agencies; the insurance agencies include “Social Medical Insurance funded by PRC and Heilongjiang Province” and “Heilongjiang Province New Rural Cooperative Medical Care System”. The Company utilizes an online system maintained by the social insurance agencies for patients’ who are covered by social insurance agencies.

F-9

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Revenue recognition (continued)

•

The Company records patients’ information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system.

•

At the time of check out, the Company collects payment for services the patients are liable for and records accounts receivable from the social insurance agencies for the portion of services covered by the social insurances. In the case that the patients have made payment during the in-patient services period, the Company refunds any amount in excess of the portion they are liable for.

•

The Company is responsible for submitting supporting documents of patient services provided to the social insurance agencies for their review. The Company also requires reconciling its records with the social insurance agencies once a month. Once the social insurance agencies approve the reconciliation, the insurance agencies will settle the accounts receivable balance in the next month following the approval.

Income taxes

The Company adopts FASB ASC Topic 740, “Income Taxes,” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740-10, “Accounting for Uncertainty in Income Taxes” requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements. Tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or deferred tax asset valuation allowance.

As a result of the implementation of ASC 740-10, the Company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10. The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation. The adoption of ASC 740-10 did not have a material impact on the Company’s unaudited consolidated financial statements.

Enterprise income tax is defined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC, income tax is payable by enterprises at a rate of 25% of their taxable income.

Jiarun’s medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the “PRC Business Tax Tentative Regulations” Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company’s medical services have been exempted from business tax since March 1, 2006.

In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $2,072 and $3,172 for the nine months ended September 30, 2017 and 2016, respectively, to support the local tax bureau’s economical obligations.

F-10

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 2. SUMMARIES OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Earnings per share

Basic earnings per common share is computed by using net income divided by the weighted average number of shares of common stock outstanding for the periods presented. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding for the periods presented.

Recently accounting pronouncements

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), aimed at making leasing activities more transparent and comparable. The new standard requires substantially all leases be recognized by lessees on their balance sheet as a right-of-use asset and corresponding lease liability, including today’s operating leases. For public business entities, the standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. For all other entities, the standard is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early application is permitted for all entities. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial condition, results of operations and cash flows.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU No. 2016-18”). ASU No. 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, restricted cash and restricted cash equivalents. Therefore, amounts generally described as restricted cash should be included with cash and cash equivalents when reconciling the beginning of period and end of period total amounts shown on the statement of cash flows. ASU No. 2016-18 is effective for annual periods beginning after December 15, 2017, including interim periods within those fiscal years. The Company elected to early adopt ASU No. 2016-18 for the reporting period ending December 31, 2016, and was applied retrospectively. As a result of adoption of ASU No. 2016-18, the Company no longer presents the changes within restricted cash in the consolidated statements of cash flows.

In January 2017, the FASB issued Accounting Standards Board Update No. 2017-01: Business Combinations (Topic 805) - Clarifying the Definition of a Business (“ASU 2017-01”). The ASU clarifies the definition of business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. ASU 2017-01 will be effective for the Company’s fiscal year beginning January 1, 2018, and subsequent interim periods with prospective application with impacts on the Company’s consolidated financial statements that may vary depending on each specific acquisition. Early adoption is conditionally permitted.

In March 2017, the FASB issued ASU No. 2017-08, Receivables – Nonrefundable Fees and Other Costs (Subtopic 310-20), Premium Amortization on Purchased Callable Debt Securities. Under current GAAP, entities normally amortize the premium as an adjustment of yield over the contractual life of the instrument. This guidance shortens the amortization period for certain callable debt securities held at a premium to the earliest call date. This update is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The adoption of ASU No. 2017-08 is not expected to have a material impact on the Company’s consolidated financial statements.

In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation: (Topic 718): Scope of Modification Accounting. ASU 2017-09 provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. The Company is in the process of assessing the impact that the adoption of this ASU will have on our consolidated financial statements.

We do not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the consolidated financial position, statements of operations and cash flows.

F-11

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 3. Accounts Receivable, Net

	September 30		December 31
	2017		2016
	(Unaudited)
Accounts receivable	$	4,036,283	$	3,359,619
Less: allowance for doubtful debts		24,794		24,119
	$	4,011,489	$	3,335,500

The Company experienced nil bad debts during the nine months ended September 30, 2017 and 2016.

NOTE 4. Inventories

At September 30, 2017 and December 31, 2016, inventories consist of the following:

	September 30		December 31
	2017		2016
	(Unaudited)
Western medicine	$	630,342	$	548,724
Chinese herbal medicine		11,967		9,113
Medical material		438,511		241,630
Other material		2,422		1,773
	$	1,083,242	$	801,240

NOTE 5. Prepayment

At September 30, 2017 and December 31, 2016, prepayment consists of the following:

	September 30		December 31
	2017		2016
	(Unaudited)
Deposits on medical equipment	$	419,642	$	221,083
Heating fees		-		86,515
Others		394,889		211,124
	$	814,531	$	518,722

NOTE 6. Property and Equipment

At September 30, 2017 and December 31, 2016, property and equipment, at cost, consist of:

	September 30,			December 31,
	2017			2016
	(Unaudited)
Transportation equipment	$	852,332		$	715,646
Medical equipment		10,266,210			9,282,026
Electrical equipment		1,389,725			1,310,927
Office equipment and others		112,637			93,283
Buildings		15,048,090			13,982,919
Software		142,996			137,028
Total fixed assets at cost		27,811,990			25,521,829
Accumulated depreciation		(3,303,722	)		(2,247,649	)
Total fixed assets, net	$	24,508,268		$	23,274,180

The Company recorded depreciation expense of $936,827 and $779,321 for the nine months ended September 30, 2017 and 2016, and $322,476 and $282,302 for the three months ended September 30, 2017 and 2016, respectively.

F-12

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 7. Long term deferred expenses

On May 7, 2015, July 3, 2015 and October 16, 2015, Jiarun entered into three lease agreements to lease medical equipment from Hair Finance Leasing (China) Co., Ltd. (“Hair”), a third party, for a five-year period, in which Jiarun is required to pay consulting fee to Hair for the services provided over the five years. The consulting fee paid but attributable to the current and subsequent accounting periods was accounted for as deferred expenses and long term deferred expenses. The current portion of the prepaid consulting fee was recorded as deferred expenses $67,797 and $64,967 as of September, 2017 and December 31, 2016. The long-term deferred expenses were $121,001 and $164,676 as of September, 2017 and December 31, 2016.

The Company recorded consulting fee of $49,715 and $51,425 for the nine months ended September 30, 2017 and 2016, and $16,903 and $16,912 for the three months ended September 30, 2017 and 2016, respectively

NOTE 8. Capital Lease Obligations and Deposit for Capital Leases

On June 5, 2013, Jiarun entered into a lease agreement to lease hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. The Leasing terms consist of principal plus 30 payments. Each payments will be made on an annual basis when RMB7,000,000 per payment will be paid upfront for each leasing period. The first payment was made on September, 2014. At the end of the leasing period, a final payment will be made to settle the total leasing amount. Both parties agreed for Jiarun to pay RMB3,000,000 as deposit at the execution of the Leasing agreement, which will be deducted from the final rental settlement. The lending interest rate was calculated at 6.55%, which is the benchmark interest rate announced from The People’s Bank of China. After the completion of all payments, the ownership of the lease item will be transferred to Jiarun.

The leasing agreement for our hospital building contains the following provisions:

•

Rental payments of RMB7,000,000 (equivalent to $1,144,913) per year, payable at the beginning of September.

•

An option allowing the lessor to extend the lease for thirty years beyond the last renewal option exercised by the Company.

•

A guarantee by the Company that the lessor will realize $nil, from selling the asset at the expiration of the lease This lease is a capital lease because its term (30 years) exceeds 75% of the building’s estimated economic life. In addition, the present value ($15,185,032) of the minimum lease payments exceeds 90% of the fair value of the building ($15,721,295).

•

Accumulated annual amounts resulting from applying an interesting rate 6.55% to the balance of the lease obligation at the beginning of each year. The lease obligation is increased by the amount of the prior year’s interest, the amount of the net rental payment at the beginning of each year; and this amount represents the guaranteed residual value at the end of the lease term.

On May 7, 2015, July 3, 2015, October 16, 2015, May 10, 2016, July 5, 2016, December 16, 2016 and April 1, 2017, Jiarun entered into several lease agreements to lease medical equipment and elevator from three lease finance companies, which are all third parties, for three to five-year periods, in which Jiarun is required to make monthly or quarterly payments toward the leases. The Company was also required to pay deposits up front, which deposits will later be used to offset against the last quarterly payment. The medical equipment and elevator will be transferred to Jiarun upon the completion of the agreement.

These leases have been classified as capital leases. The cost of the medical equipment included in these leases is included in the consolidated balance sheets as property and equipment and construction in progress.

F-13

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 8. Capital Lease Obligations and Deposit for Capital Leases (Continued)

The future minimum lease payments for annual capital lease obligation as of September 30, 2017, are as follows:

Year	Amounts (Unaudited)
2017	$	561,417
2018		2,261,908
2019		2,234,325
Thereafter		12,603,580
Total	$	17,661,230

The Company recorded finance lease fees of $969,036 and $1,028,871 for the nine months ended September 30, 2017 and 2016, and $328,706 and $349,488 for the three months ended September 30, 2017 and 2016, respectively.

NOTE 9. Short-term Bank Loan

	September 30		December 31
	2017		2016
	(Unaudited)
Short- term bank loan	$	435,769	$	-

As of September 30, 2017, the above bank loan was acquired for working capital and capital expenditure purposes. The loan was primarily obtained from Harbin Bank with interest rate of 6.09% per annum, the loan contract was started from January 19, 2017 to January 18, 2018, and the loan was received on January 24, 2017. The interest expenses were $17,226 and $19,384 for the nine months ended September 30, 2017 and 2016, respectively, and $6,737 and $6,775 for the three months ended September 30, 2017 and 2016, respectively.

NOTE 10. Non-controlling Interests

Jiarun is the Company’s majority-owned subsidiary which is consolidated in the Company’s financial statements with a non-controlling interest (“NCI”) recognized. The Company holds 70% interest of Jiarun as of September 30, 2017 and December 31, 2016.

As of September 30, 2017 and December 31, 2016, NCI in the consolidated balance sheet was $6,562,703 and $5,052,519, respectively. For the nine months ended September 30, 2017, the comprehensive income attributable to shareholders’ equity and NCI is $3,473,860 and $1,510,184, respectively. For the nine months ended September 30, 2016, the comprehensive income attributable to shareholders’ equity and NCIs is $2,352,946 and $1,055,531, respectively. For the three months ended September 30, 2017, the comprehensive income attributable to shareholders’ equity and NCI is $1,258,966 and $539,418 respectively. For the three months ended September 30, 2016, the comprehensive income attributable to shareholders’ equity and NCIs is $785,934 and $344,420, respectively.

F-14

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 11. Revenue

The Company’s revenue consists of medicine sales and patient care revenue.

	Nine Months Ended September 30,
	2017		2016
	(Unaudited)		(Unaudited)
Medicine:
Western medicine	$	5,879,515	$	4,332,469
Chinese medicine		1,211,547		1,093,906
Herbal medicine		265,108		217,522
Total medicine	$	7,356,170	$	5,643,897

Patient services:
Medical consulting	$	5,058,274	$	3,772,599
Medical treatment		3,934,189		3,413,746
Others		243,673		127,870
Total patient services	$	9,236,136	$	7,314,215

	$	16,592,306	$	12,958,112

	Three Months Ended September 30,
	2017		2016
	(Unaudited)		(Unaudited)
Medicine:
Western medicine	$	1,917,785	$	1,440,135
Chinese medicine		399,142		340,944
Herbal medicine		90,247		65,819
Total medicine	$	2,407,174	$	1,846,898

Patient services:
Medical consulting	$	1,825,022	$	1,222,847
Medical treatment		1,286,639		1,146,895
Others		204,262		40,604
Total patient services	$	3,315,923	$	2,410,346

	$	5,723,097	$	4,257,244

F-15

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 12. Income Tax Expense

The Company uses the asset-liability method of accounting for income taxes prescribed by ASC 740 Income Taxes. The Company and its subsidiaries each files their taxes individually.

United States

JHCC is subject to the United States of America Tax law at tax rate of 34% for its taxable income. No provision for the US federal income taxes has been made as the Company had no US taxable income for the periods presented, and its earnings are generated from PRC.

BVI

JHCL was incorporated in the BVI and, under the current laws of the BVI, it is not subject to income tax.

Hong Kong

Runteng was incorporated in Hong Kong and is subject to Hong Kong profits tax. Runteng is subject to Hong Kong taxation on its activities conducted in Hong Kong and income arising in or derived from Hong Kong. The applicable statutory tax rate is 16.5%.

PRC

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

Jiarun was incorporated in accordance with the law of medical and health institutions, mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.

In considering the achievement of the hospital, it could not have been done without the support of local authorities, Jiarun hospital has voluntarily paid income tax of $2,072 and $3,172 for the nine months ended September 30, 2017 and 2016, respectively to support the local tax bureau's economical obligations.

NOTE 13. Related Party Transactions

The following is the list of the related parties to which the Group has transactions with:

(a) Junsheng Zhang, the Chairman of the Company

(b) Harbin Baiyi Real Estate Development Co., Ltd (“Baiyi”), owned by Junsheng Zhang

(d) Harbin Jiarun Pharmacy Co., Limited owned by Junsheng Zhang

(e) Heilongjiang Province Runjia Medical Equipment Company Limited owned by Junsheng Zhang

(f) Jiarun Super Market Co., Ltd. owned by Junsheng Zhang

(g) Harbin Qi-run pharmacy limited owned by Junsheng Zhang

(h) Yanhua Xing and Weiguang Song, the former shareholder of JHCL

Amount due from related parties

Amount due from related parties consisted of the following as of the periods indicated:

	September 30,		December 31,
Name of related parties	2017		2016
Harbin Baiyi Real Estate Development Co., Ltd.	$	3,591,787	$	1,754,987
Junsheng Zhang		46,500		46,500
Yanhua Xing		2,450		2,450
Weiguang Song		1,050		1,050
	$	3,641,787	$	1,804,987

F-16

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 13. Related Party Transactions (Continued)

Amount due from Baiyi was mainly represented the deposit and progress payment for the new outpatient building which was constructed by Baiyi. The Company signed a purchase agreement with Baiyi to acquire the first to eighth floor of a building which is under construction by Baiyi. The total amount for the purchased property is approximately RMB63,900,000 ($9,579,894). The Company had made a deposit of $1,451,136 in 2016, and progress payment of $2,945,271 accordingly. The total payment was $3,591,787 as of September 30, 2017.

Amount due from Junsheng Zhang, Yanhua Xing and Weiguang Song, who are the prior shareholders of JHCL, was mainly for the paid-in capital to be paid.

Amount due to related parties

Amount due to related parties consisted of the following as of the periods indicated:

	September 30,		December 31,
Name of related parties	2017		2016
Harbin Jiarun Pharmacy Co., Ltd	$	90,382	$	-
Heilongjiang Province Runjia Medical Equipment Co., Ltd		3,356		18,382
Harbin Qi-run pharmacy Co., Ltd		11,961		6,947
Junsheng Zhang		50,000		-
	$	155,699	$	25,329

Amount due to Harbin Jiarun Pharmacy Co., Ltd., Harbin Qi-run pharmacy Co., Ltd and Heilongjiang Province Runjia Medical Equipment Company Limited were mainly for the balance for purchase of medicine and medical material from these three companies.

Amounts due to Junsheng Zhang represented the balance paid by Mr. Zhang for the daily operation of the Company.

Related parties’ transactions

Purchase of medicine and medical material from related parties consisted of the following for the periods indicated:

	For nine months ended September 30,
Name of related parties	2017		2016
Heilongjiang Dahua Medicine Wholesale Co., Ltd	$	-	$	552,682
Harbin Jiarun Pharmacy Co., Ltd		146,083		143,530
Heilongjiang Province Runjia Medical Equipment Co., Ltd		393		58,899
Harbin Qi-run pharmacy Co., Ltd		24,738		19,185
	$	171,214	$	774,296

Deposits for capital leases and Capital lease obligations

On June 5, 2013, Jiarun entered into a Lease Agreement to lease a new hospital building from Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. As of September 30, 2017, the Company has a balance of deposits for capital leases and capital lease obligations of $450,796 and $11,992,336 respectively. As of December 31, 2016, the Company has a balance of deposits for capital leases and capital lease obligations of $431,980 and $13,896,989 respectively.

F-17

JRSIS HEALTH CARE CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(AMOUNTS IN USD)

NOTE 14. Basic and Diluted Earnings Per Share

Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares comprise shares issuable upon the exercise of share based awards, using the treasury stock method. The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations for income from continuing operations is shown as follows:

	Nine Months Ended September 30,
	2017		2016
	(Unaudited)		(Unaudited)
Numerator:
Net income available to common stockholders	$	3,080,739	$	2,548,115
Denominator:
Basic and diluted weighted-average number of shares outstanding		13,915,000		13,915,000
Net income per share:
Basic and diluted	$	0.2214	$	0.1831

NOTE 15. Contingencies and Commitment

There was no contingency as of September 30, 2017 and December 31, 2016.

NOTE 16. Subsequent Events

The Management of the Company determined that there were no reportable subsequent events to be disclosed.

F-18

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of such financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates, including those related to useful lives of real estate assets, bad debts, impairment, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There can be no assurance that actual results will not differ from those estimates. The analysis set forth below is provided pursuant to applicable SEC regulations and is not intended to serve as a basis for projections of future events. See “Cautionary Statement Regarding Forward Looking Statements” above.

Overview

Harbin Jiarun Hospital Company Limited (“Jiarun”) was established in Harbin in the Province of Heilongjiang of the People’s Republic of China (“PRC”) by the owner Junsheng Zhang on February 17, 2006.

Jiarun is a private hospital serving patients on a municipal and county level and providing both Western and Chinese medical practices to the residents of Harbin. Jiarun specializes in the areas of Pediatrics, Dermatology, ENT, Traditional Chinese Medicine (TCM), Ophthalmology, Internal Medicine Dentistry, General Surgery, Rehabilitation Science, Gynecology, General Medical Services, etc.

On November 20, 2013, Junsheng Zhang, the officer of Jiarun Hospital established JRSIS Health Care Corporation, a Florida corporation (“JHCC” or the “Company”). On February 25, 2013, the officer of Jiarun Hospital established JRSIS Health Care Limited ("JHCL"), a wholly owned subsidiary of the Company, and On September 17, 2012, the officer of Jiarun Hospital established Runteng Medical Group Co., Ltd (“Runteng”), a wholly owned subsidiary of JHCL. Runteng, a Hong Kong registered Investment Company, holds a 70% ownership interest in Harbin Jiarun Hospital Company Ltd, a Heilongjiang registered company.

On December 20, 2013, the Company acquired 100% of the issued and outstanding capital stock of JRSIS Health Care Limited, a privately held Limited Liability Company registered in the British Virgin Islands for 12,000,000 shares of our common stock. JHCL, through its wholly owned subsidiary, Runteng Medical Group Co., Ltd, holds majority ownership in Jiarun, a company duly incorporated, organized and validly existing under the laws of China. As the parent company, JHCC rely on Jiarun to conduct 100% of our businesses and operations.

We have two sources of patient revenues: in-patient service revenues and out-patient service revenues. In addition to provide services to our patients, we also sell pharmaceutical medicines to our patients. Revenues from such sales are included in either our in-patient service revenues or our out-patient service revenues. Our revenues come from individuals as well as third-party payers, including PRC government programs and insurance providers, under which the hospital is paid based upon local government established charges. Revenue from the sale of medicine is recognized when it is both earned and realized. The Company’s policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine. Patient service revenue is recognized when it is both earned and realized. The Company’s policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.

Plan of Operation

Over the next twelve months, we will concentrate on the following two areas to grow our operations:

●

Capital and Funding – Seek to obtain capital from all available sources to complete our hospital expansion and acquisition targets.

●

Advertising and Marketing – Work with several marketing companies to develop brand identity, marketing materials, and update our web site. Utilize all available marketing venues and public relations opportunities to promote the Company and its medicine and services. In April, 2014, we also bought a mobile clinic to provide free health examinations in the hospital area. Management believes this free service will bring us much higher brand reputation and potential customers locally.

Critical Accounting Policies and Management Estimates

Our discussion and analysis of our financial condition and results of operations relates to our consolidated financial statements, which have been prepared in accordance with the United States generally accepted accounting principles ("U.S. GAAP"). The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. All significant inter-company accounts and transactions have been eliminated in consolidation.

Use of estimates

Revenue Recognition

Medicine sales

Revenue from the sale of medicine is recognized when it is both earned and realized. The Company's policy is to recognize the sale of medicine when the title of the medicine, ownership and risk of loss have transferred to the purchasers, and collection of the sales proceeds is reasonably assured, all of which generally occur when the patient receives the medicine.

Given the nature of this revenue source of the Company's business and the applicable rules guiding revenue recognition, the revenue recognition practices for the sale of medicine do not contain estimates that materially affect results of operations nor any policy for return of products.

Patient Services

In accordance with the medical licenses of Jiarun, the approved medical patient service scope of the Company includes medical consulting, surgery, obstetrics and gynecology, pediatrics, anesthesia, clinic laboratory, medical imaging, and traditional Chinese medicine, etc.

Patient service revenue is recognized when it is both earned and realized. The Company's policy is to recognize patient service revenue when the medical service has been provided to the patient and collection of the revenue is reasonably assured.

Patients who are not covered by social insurance are liable for the total cost of medical treatment.

For in-patient medical services, the Company estimates the approximate fee the patients will spend in the hospital based on patients' symptom. This is when the patients check in to the hospital. At that time, the Company collects the estimated fees from the patient and records the payment as deposits received.

Patients covered by social insurance will receive a portion or full medical services reimbursed or paid by the social insurance agencies via prepaid cards or insurance claim settlement process.

Settlement process

The Company records patients’ information in the social insurance system at check in. The system determines the covered portion and amounts based on the information input to the system.

Income Taxes and Uncertain Tax Positions

The Company adopts FASB ASC Topic 740, "Income Taxes," which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

ASC 740-10, “Accounting for Uncertainty in Income Taxes” requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements, tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not threshold should be derecognized in the first subsequent financial reporting period in which that threshold is no longer met.

As a result of the implementation of ASC 740-10, the Company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10. The Company recognized no material adjustments to liabilities or shareholder's equity as a result of the implementation. The adoption of ASC 740-10 did not have a material impact on the Company's unaudited consolidated financial statements.

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

Accounts Receivable

Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts as needed. The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote

Property and equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis reflective of the useful lives of the assets. When assets are retired or disposed, the asset's original cost and related accumulated depreciation are eliminated from accounts and any gain or loss is reflected in income.

Buildings and improvement	10-40 years
Medical equipment	5-15 years
Transportation instrument	5-10 years
Office equipment	5-10 years
Electronic equipment	5-10 years
Software	5-10 years

Foreign currency transactions and translations

JHCC and JHCL’s functional currency is the United States dollar ("US$"). Runteng's functional currency is the Hong Kong dollar ("HK$"). The functional currency of Jiarun is the Renminbi ("RMB").

Results of Operations for Three Months Ended September 30, 2017 and 2016

The following table shows key components of the results of operations during three months ended September 30, 2017 and 2016:

	Three Months Ended September 30,						Change
	2017			2016			$			%

Revenue:
Medicine	$	2,407,174		$	1,846,898		$	560,276			30	%
Patient services		3,315,923			2,410,346			905,577			38	%
Total revenue		5,723,097			4,257,244			1,465,853			34	%
Operating costs and expenses:
Cost of medicine sold		1,573,420			1,161,959			411,461			35	%
Medical consumables		648,258			382,891			265,367			69	%
Salaries and benefits		934,950			720,860			214,090			30	%
Office supplies		249,389			70,142			179,247			256	%
Vehicle expenses		22,842			17,374			5,468			31	%
Utilities expenses		74,222			76,027			(1,805	)		(2	)%
Rentals and leases		5,877			-			5,877
Advertising and promotion expenses		22,869			15,868			7,001			44	%
Interest expense		351,137			339,737			11,400			4	%
Professional fee		15,869			19,351			(3,482	)		(18	)%
Depreciation		322,476			282,302			40,174			14	%
Total operating costs and expenses		4,221,309			3,086,511			1,134,798			37	%
Earnings from operations before other income and income taxes		1,501,788			1,170,733			331,055			28	%
Other income		7,108			(857	)		7,965			(929	)%
Earnings from operations before income taxes		1,508,896			1,169,876			339,020			29	%
Income tax		437			866			(429	)		(50	)%
Net income		1,508,459			1,169,010			339,449			29	%
Less: net income attributable to non-controlling interests		452,538			355,950			96,588			27	%
Net income attributable to the Company	$	1,055,921		$	813,060		$	242,861			30	%
Comprehensive income:
Foreign currency translation adjustment attributable to non-controlling interests		(86,880	)		11,530			(98,410	)		(854	)%
Foreign currency translation adjustment attributable to the Company		(203,045	)		27,126			(230,171	)		(849	)%
Comprehensive income	$	1,798,384		$	1,130,354		$	668.030			59	%

Revenue

Operating revenue for the three months ended September 30, 2017, which resulted primarily from medicine revenue and patient services revenue, was $5,723,097, an increase of 34% as compared with the operating revenue of $4,257,244 for the three months ended September 30, 2016. The increase was primarily a result of the number of treated inpatients growing to 3,700 patients, about 290 more than the 3,410 patients treated in three months ended September 30, 2016.

Costs and Expenses

Total costs and expenses were $4,221,309 for the three months ended September 30, 2017, an increase of $1,134,798 or 37% as compared to $3,086,511 for the same period of 2016. This increase was primarily due to significant increase of cost of medicine sold of $411,461, medical consumables of $265,367, salaries and benefits of $214,090.

Cost of medicine sold

Cost of medicine sold mainly consists of cost of Western medicine, Chinese medicine and herbal medicine. Total cost of medicine sold was $1,573,420 for the three months ended September 30, 2017, an increase of $411,461 or 35% as compared to $1,161,959 for the same period of 2016. This increase was primarily due to significant increases in sales of Western medicine and Chinese medicine. For the three months ended September 30, 2017, the cost of Western medicine and Chinese medicine were $1,532,487 as compared to $1,136,255 for the same period of 2016.

Medical consumables

Medical consumables mainly consist of materials expenses, repair cost, medical film expenses and test reagent. Total medical consumables were $648,258 for the three months ended September 30, 2017, an increase of $265,367 or 69% as compared to $382,891 for the same period of 2016. The increase was mainly a result of increase in materials expenses of $121,747.

Salaries and benefits

Salaries and benefits mainly consist of salary expenses, and social insurance expenses. Total salaries and benefits were $934,950 for the three months ended September 30, 2017, an increase of $214,090 or 30% as compared to $720,860 for the same period of 2016. The increase was mainly a result of increase in salaries expenses of $199,215 and increase in social insurance expenses of $14,782. The number of employees was 572, an increase of 93 as compared to 479 for the same period of 2016.

Income Taxes

Enterprise income tax is defined under the Provisional Regulations of PRC Concerning Income Tax on Enterprises promulgated by the PRC. Income tax is payable by enterprises at a rate of 25% of their taxable income.

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

Jiarun was incorporated in accordance with the law of medical and health institutions to mainly provide medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.

In considering the achievements of the hospital, they could not have been reached without the support of local authorities. Jiarun hospital has voluntarily paid income tax of $437 and $866 for the three months ended September 30, 2017 and 2016, respectively to support the local tax bureau's economical obligations.

Income from Operations and Net income

Income from Operations was $1,501,788 for the three months ended September 30, 2017, as compared with operating income of $1,170,733 for the three months ended September 30, 2016. The Company’s net income for the three months ended September 30, 2017 was $1,508,459 representing an increase of $339,449 or 29%, over $1,169,010 for the three months ended September 30, 2016. The increases in income from operations and net income for the three months ended September 30, 2017, were primarily due to aforementioned changes in operating revenue and operating expenses.

Results of Operations for the nine months Ended September 30, 2017 and 2016

The following table shows key components of the results of operations during nine months ended September 30, 2017 and 2016:

	Nine Months Ended September 30,					Change
	2017			2016		$			%

Revenue:
Medicine	$	7,356,170		$	5,643,897	$	1,712,273			30	%
Patient services		9,236,136			7,314,215		1,921,921			26	%
Total revenue		16,592,306			12,958,112		3,634,194			28	%
Operating costs and expenses:
Cost of medicine sold		4,799,786			3,374,138		1,425,648			42	%
Medical consumables		1,755,032			1,200,169		554,863			46	%
Salaries and benefits		2,643,753			2,106,103		537,650			26	%
Office supplies		581,678			220,380		361,298			164	%
Vehicle expenses		65,667			38,770		26,897			69	%
Utilities expenses		293,706			308,358		(14,652	)		(5	)%
Rentals and leases		5,877			-		5,877			100	%
Advertising and promotion expenses		59,064			92,975		(33,911	)		(36	)%
Interest expense		980,451			1,030,949		(50,498	)		(5	)%
Professional fee		54,182			126,272		(72,090	)		(57	)%
Depreciation		936,827			779,321		157,506			20	%
Total operating costs and expenses		12,176,023			9,277,435		2,898,588			31	%
Earnings from operations before other income and income taxes		4,416,283			3,680,677		735,607			20	%
Other income (expenses)		(13,155	)		3,900		(17,055	)		(437	)%
Earnings from operations before income taxes		4,403,128			3,684,577		718,552			20	%
Income tax		2,072			3,172		(1,100	)		(35	)%
Net income		4,401,056			3,681,405		719,651			20	%
Less: net income attributable to non-controlling interests		1,320,317			1,133,290		187,027			17	%
Net income attributable to the Company	$	3,080,739		$	2,548,115	$	532,624			21	%
Comprehensive income:
Foreign currency translation adjustment attributable to non-controlling interests		(189,867	)		77,759		(267,626	)		(344	)%
Foreign currency translation adjustment attributable to the Company		(393,121	)		195,169		(588,290	)		(301	)%
Comprehensive income	$	4,984,044		$	3,408,477	$	1,575,567			46	%

Revenue

Operating revenue for the nine months ended September 30, 2017, which resulted primarily from medicine revenue and patient services revenue, was $16,592,306, an increase of 28% as compared with the operating revenue of $12,958,112 for the nine months ended September 30, 2016. The increase was primarily a result of the number of treated inpatients growing to 12,725 patients, about 2,167 more than the 10,558 patients treated in nine months ended September 30, 2016.

Costs and Expenses

Total costs and expenses were $12,176,023 for the nine months ended September 30, 2017, an increase of $2,898,588 or 31% as compared to $9,277,435 for the same period of 2016. This increase was primarily due to significant increases in medical consumables of $554,863, and increases in cost of medicine supplies of approximately $1,425,648, and increase in salaries and benefits of $537,650.

Cost of medicine sold

Cost of medicine sold mainly consists of cost of Western medicine, Chinese medicine and herbal medicine. Total cost of medicine sold was $4,799,786 for the nine months ended September 30, 2017, an increase of $1,425,648 or 42% as compared to $3,374,138 for the same period of 2016. This increase was primarily due to significant increases in cost of Western medicine and Chinese medicine of $1,391,634. For the nine months ended September 30, 2017, the cost of Western medicine and Chinese medicine were $4,681,320, as compared to $3,289,686 for the same period of 2016.

Medical consumables

Medical consumables mainly consist of materials expenses, medical film expenses and test reagent. Total medical consumables were $1,755,032 for the nine months ended September 30, 2017, an increase of $554,863 or 46% as compared to $1,200,169 for the same period of 2016. The increase was mainly a result of increase in materials expenses of $295,793 and increase in repair cost of $69,988.

Salaries and benefits

Salaries and benefits mainly consist of salaries expenses, and social insurance expenses. Total salaries and benefits were $2,643,753 for the nine months ended September 30, 2017, an increase of $537,650 or 26% as compared to $2,106,103 for the same period of 2016. The increase was mainly a result of increase in salaries expenses of $492,455. The number of employees was 555, an increase of 94 as compared to 461 for the same period of 2016.

Income Taxes

Jiarun's medical services have been exempt from enterprise income tax since March 1, 2006, which has been approved by the Local Taxation Bureau.

Jiarun was incorporated in accordance with the law of medical and health institutions mainly provides medical services, with the "PRC Business Tax Tentative Regulations" Article 8 (3) medical service income tax-free provisions (hospital, clinics and other medical institutions to provide medical services shall be exempt from business tax). The Company's medical services have been exempted from business tax since March 1, 2006.

In considering the achievements of the hospital, they could not have been reached without the support of local authorities, Jiarun hospital has voluntarily paid income tax voluntary of $2,072 and $3,172 for the nine months ended September 30, 2017 and 2016, respectively, to support the local tax bureau's economical obligations.

Income from Operations and Net income

Income from Operations was $4,416,283 for the nine months ended September 30, 2017, as compared with operating income of $3,680,677 for the nine months ended September 30, 2016. The Company’s net income for the nine months ended September 30, 2017 was $4,401,056 representing an increase of $719,651 or 20%, over $3,681,405 for the nine months ended September 30, 2016. The increases in income from operations and net income for the nine months ended September 30, 2017 were primarily due to aforementioned changes in operating revenue and operating expenses.

Liquidity and Capital Resources

The accompanying financial statements have been prepared for the Company to continue as a going concern which contemplates, among other things, the realization of assets and satisfaction of liabilities in the ordinary course of business.

As of September 30, 2017, the Company had $999,648 of cash and cash equivalents.

We are presently able to meet our obligations as they come due. As of September 30, 2017, we had non-controlling interest of $6,562,703 and shareholders’ equity of $16,670,898.

We anticipate that our future liquidity requirements will arise from the need to fund our growth, pay current obligations and future capital expenditures. The primary sources of funding for such requirements are expected to be cash generated from operations and raising additional funds from the public offering and/or debt financing. However, we can provide no assurances that we will be able to generate sufficient cash flow from operations and/or obtain additional financing on terms satisfactory to us, if at all, to remain a going concern.

Cash Flows and Capital Resources

We believe that we will generate cash flow from our business, which, along with our available cash, will provide sufficient liquidity and financial flexibility. Our cash flows are summarized below:

	Nine Months Ended September 30,
	2017			2016
Net cash provided by operating activities		4,159,891			3,914,023
Net cash used in investing activities		(2,606,774	)		(2,918,429	)
Net cash used in financing activities		(1,436,584	)		(747,429	)
Effect of exchange rate fluctuation on cash and cash equivalents		(7,547	)		(3,296	)
Net (increase) decrease in cash and cash equivalents		108,986			244,869
Cash and cash equivalents, beginning of period		890,662			352,153
Cash and cash equivalents, ending of period	$	999,648		$	597,022

Net Cash provided by Operating Activities

For the nine months ended September 30, 2017, we had positive cash flow from operating activities of $4,159,891, an increase of $245,868 from the same period of 2016, during which we had cash flow from operating activities of $3,914,023. The increase in net cash used in operating activities was mainly as a result of the net income for the nine months ended September 30, 2017, increased by $719,651 as compared to the nine months ended September 30, 2016, and the addition of Amount to Accounts payable items totaling $409,740, which was due to the purchasing of medicines and equipment.

Net Cash Used in Investing Activities

Net cash used in investing activities for the nine months ended September 30, 2017, was $2,606,774, compared to net cash used in investing activities of $2,918,429 for the nine months ended September 30, 2016. The cash used in investing activities for the nine months ended September 30, 2017, was mainly used for the purchase of medical equipment.

Net Cash Used in Financing Activities

Net cash used in financing activities for the nine months ended September 30, 2017, was $1,436,584, as compared to net cash used in financing activities of $747,429 for the nine months ended September 30, 2016. The cash used in financing activities for the nine months ended September 30, 2017, was mainly provided by proceeds from shareholders $720,000 and from a short-term bank loan of $408,836 and payments on capital lease obligation of $2,565,420.

Trends, Events and Uncertainties

The China Ministry of Health, as well as other related agencies, may change the prices we can charge for medical services, drugs and medications. We cannot predict the impact of these proposed changes since the changes are not fully defined and we do not know whether such changes will ever be implemented or when they may take effect.

In December 2014, our operations moved into the new building. We have finished most of the decoration of the new building, and part of the expansion of medical facilities and purchases of new medical equipment. The hospital will need more medical facilities to update the medical equipment and acquire one pharmaceuticals wholesale and one medicine retail company. The new hospital building is being constructed by Harbin Baiyi Real Estate Development Co., Ltd, which is owned by Junsheng Zhang, a related party. The building was leased from the related party by financial leasing. The price of the Leasing Agreement referred to the local market price and audited by the auditor. The Leasing Agreement terms consist of 30 payments. Each payment will be made on an annual basis when 7 million RMB per payment will be paid upfront for each leasing period. The first payment was made on September 1, 2014. At the end of the leasing period, a final payment will be made to settle the total leasing amount. Both parties agreed for the leasee to pay 3 million RMB as a deposit at the execution of the Leasing Agreement, which will be deducted from the final rental settlement. The lending interest rate was calculated at 6.55%, which is the benchmark interest rate announced from The People’s Bank of China. After the completion of all payments, the ownership of the lease item will be transferred to the Jiarun.

We plan to acquire other hospitals and companies involved in the healthcare industry in the PRC using cash and shares of our common stock. Substantial capital may be needed for these acquisitions, and we may need to raise additional funds through the sale of our common stock, debt financing or other arrangements. We do not have any commitments or arrangements from any person to provide us with any additional capital. Additional capital may not be available to us, or if available, on acceptable terms, in which case we would not be able to acquire other hospitals or businesses in the healthcare industry.

Other than the factors listed above we do not know of any trends, events or uncertainties that have had or are reasonably expected to have a material impact on our net sales or revenues or income from continuing operations. Our business is not seasonal in nature.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet items reasonably likely to have a material effect on our financial condition.

Recent Accounting Pronouncements

Recent accounting pronouncements issued by the FASB, the AICPA and the SEC did not, or are not believed by management to, have a material effect on the Company’s present or future consolidated financial statements.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company”, we are not required to provide the information required by this Item.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluations of Disclosure Controls and Procedures

Under the supervision and with the participation of our management team, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of December 31, 2004. Based on this evaluation, we concluded that our disclosure controls and procedures are effective in timely alerting them to material information required to be included in our periodic reports.

Changes in Internal Control over Financial Reporting

During the period covered by this report, there has been no change in our internal control over financial reporting that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS.

The Company has no knowledge of existing or pending legal proceedings against the Company, nor is the Company involved as a plaintiff in any proceeding or pending litigation. There are no proceedings in which any of the Company’s directors, officers or any of their respective affiliates, or any beneficial stockholder, is an adverse party or has a material interest adverse to our interest.

ITEM 1A.

RISK FACTORS

As a “smaller reporting company”, we are not required to provide the information required by this Item.

ITEM 2.

UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

We did not sell or issue any shares of unregistered securities during the three months period ended September 30, 2017.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

Not applicable

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable

ITEM 5.

OTHER INFORMATION

Not applicable

ITEM 6.

EXHIBITS

INDEX TO EXHIBITS

Exhibit		Description
31.1		Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

JRSIS HEALTH CARE CORPORATION. (Registrant)

Signature	Title	Date

/s/ Lihua. Sun	Chief Executive Officer	November 13, 2017
Lihua. Sun	(Principal Executive Officer)

/s/ Xuewei. Zhang	Chief Financial Officer	November 13, 2017
Xuewei. Zhang	(Principal Financial Officer)

Attached files

JRSIS HEALTH CARE Corp Reports

Also read